The liver, as a central metabolic hub, is the primary target for treating numerous genetic and acquired disorders. CD BioGlyco provides a premier GalNAc-mRNA delivery service, leveraging the high affinity of N-acetylgalactosamine (GalNAc) for the asialoglycoprotein receptor (ASGPR) exclusively expressed on hepatocytes. By integrating GalNAc ligands with advanced delivery vehicles, we bypass the limitations of traditional lipid nanoparticles (LNPs), such as broad biodistribution and dependence on the low-density lipoprotein receptor (LDLR). Our platform ensures that mRNA payloads are sequestered specifically within liver cells, maximizing therapeutic efficacy while minimizing systemic toxicity. Whether you are developing treatments for rare metabolic diseases or chronic viral infections, CD BioGlyco delivers the precision your research demands.
As a cornerstone of our Therapeutic Nucleic Acid Development Platform, CD BioGlyco provides an industry-leading Therapeutic Oligonucleotide Delivery Service specifically engineered for GalNAc-mediated mRNA transport. We recognize that the success of mRNA-based medicine hinges on the precision of its delivery system; therefore, our service scope is meticulously designed to cover every technical milestone from initial ligand design to final formulation validation.
Our experts collaborate with you to define the target protein, desired expression levels, and the specific liver pathology being addressed. We determine the optimal delivery vehicle based on mRNA size.
We perform codon optimization and introduce chemical modifications to minimize immunogenicity. The mRNA is synthesized via in vitro transcription (IVT) and purified using high-performance liquid chromatography (HPLC) to ensure the absence of double-stranded RNA contaminants.
Depending on the project requirements, we synthesize trivalent GalNAc clusters with specific linkers (e.g., PEG-based or alkyl chains) optimized for either surface decoration of nanoparticles or direct attachment to the RNA.
We use microfluidic mixing to ensure uniform particle size and high encapsulation efficiency. For conjugates, site-specific chemistry is used to attach the GalNAc cluster to the 3' or 5' end of the mRNA without interfering with its biological activity.
We evaluate the resulting product for particle size (DLS), zeta potential, mRNA encapsulation efficiency, and GalNAc surface density. Purity is verified using gel electrophoresis and mass spectrometry.
We provide optional validation services, including ASGPR binding assays, hepatocyte uptake studies, and in vivo expression monitoring using reporter genes or target protein quantification in animal models.
Metabolic Disorder Research
Our service enables the delivery of mRNA encoding missing enzymes for diseases like methylmalonic acidemia (MMA) or glycogen storage disease (GSD), restoring normal metabolic flux directly within the hepatocytes.
Rare Liver Disease Research
We target genetic conditions such as transthyretin (TTR) amyloidosis or alpha-1 antitrypsin deficiency (AATD) by delivering therapeutic proteins or gene-editing components specifically to the liver parenchyma.
Liver Cancer (HCC) Research
We support the delivery of mRNA encoding tumor suppressors or immunostimulatory cytokines, allowing for localized treatment of HCC while sparing non-hepatic tissues from systemic side effects.
Chronic Viral Hepatitis Research
We facilitate the delivery of mRNA-based antivirals designed to target and disrupt the replication cycles of hepatitis B (HBV) and C (HCV) viruses specifically within infected liver cells.
Exceptional Targeting Specificity
By targeting the ASGPR, our GalNAc-mRNA systems achieve nearly 80-90% hepatocyte-specific uptake, significantly reducing the "off-target" accumulation in the spleen or lungs commonly seen with standard LNPs.
LDLR-Independent Pathway
Our GalNAc service works efficiently in LDLR-deficient environments, making it the gold standard for treating homozygous familial hypercholesterolemia.
Enhanced Safety and Low Toxicity
The use of biodegradable lipids and precise targeting allows for lower doses. This reduces the risk of liver enzyme elevation and systemic cytokine release, ensuring a wider therapeutic window.
Scalable and Reproducible Manufacturing
Utilizing microfluidic technology and standardized conjugation protocols, we ensure that every batch of GalNAc-mRNA meets stringent quality standards, from milligram research scales to gram-scale pilot studies.
"The GalNAc-LNP formulation provided by CD BioGlyco significantly outperformed our internal standards in a NHP model of hypercholesterolemia. The specificity for hepatocytes was remarkable, and we observed therapeutic protein levels that were 4x higher than non-targeted particles."
– A.D., Cardiovascular Research
"We struggled with endosomal escape for our mRNA conjugates until we switched to CD BioGlyco's pH-sensitive linker technology. Their team's expertise in carbohydrate chemistry is evident in the quality of the GalNAc clusters provided."
– B.G., Metabolic Disease Research
"From the initial consultation to the final characterization report, the process was seamless. The GalNAc-mRNA delivery service saved us months of optimization in our program."
– H.K., Pharmaceutical Company
CD BioGlyco is your dedicated partner for high-precision GalNAc-mRNA delivery services. By combining cutting-edge carbohydrate chemistry with robust mRNA stabilization and LNP formulation, we empower researchers to target the liver with unprecedented accuracy. Please feel free to contact us to discuss your specific requirements and provide a customized solution.
